BiotechTube

Lu AG13909

Phase 2Recruiting
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cushing's Disease

Conditions

Cushing's Disease

Trial Timeline

Jun 19, 2024 → Nov 30, 2027

NCT ID
NCT06471829

About Lu AG13909

Lu AG13909 is a phase 2 stage product being developed by Lundbeck for Cushing's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06471829. Target conditions include Cushing's Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT06471829Phase 2Recruiting
NCT05669950Phase 1/2Recruiting

Competing Products

18 competing products in Cushing's Disease

See all competitors
ProductCompanyStageHype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisoloneAstraZenecaPhase 2
52
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
77
Pasireotide sub-cutaneousNovartisPhase 3
77
osilodrostat + osilodrostat PlaceboNovartisPhase 3
77
OsilodrostatNovartisPhase 2
52
PasireotideNovartisPhase 3
77
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
85
SOM230 s.c.NovartisPhase 2
52
OsilodrostatRecordatiPre-clinical
20
Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
82
osilodrostatRecordatiPhase 2
49
OsilodrostatRecordatiPre-clinical
20
mifepristoneCorcept TherapeuticsPhase 3
72
CORT125134Corcept TherapeuticsPhase 2
47
Cushing's syndrome confirmationCorcept TherapeuticsPre-clinical
18
MifepristoneCorcept TherapeuticsPhase 3
72
mifepristoneCorcept TherapeuticsPhase 3
72
mifepristoneCorcept TherapeuticsPhase 3
72

Other Products from Lundbeck

VortioxetineApproved
82
memantine + memantine + placeboApproved
82
escitalopram + escitalopramApproved
82
BrexpiprazoleApproved
82
losartan (drug)Approved
82